semaglutide

Sales of fat-loss drugs in India have slowed after an initial surge driven by generic versions of semaglutide-based medications. Semaglutide is the active ingredient in Novo Nordisk’s Ozempic and Wegovy.

A secret shopper study revealed that telehealth sites prescribing GLP-1 medications for weight loss often operate with minimal clinical oversight, enabling fast and easy access to drugs like semaglutide and tirzepatide. The study, conducted by a Yale researcher and published in the Journal of the American Medical Association, highlights concerns about virtual care practices and the market for non-FDA-approved compounded versions due to shortages.

Peptides are widely promoted in health and beauty for benefits like weight loss and tissue repair, but many sold as 'research only' lack FDA approval. The FDA is easing access to peptides despite warnings about undermining drug approval, while experts note that only rigorously studied, FDA-approved peptides (like Tirzepatide and Semaglutide) have strong scientific backing.

Brazil's Hypera filed to launch Semavy, a semaglutide pen targeting the same drug class as Novo Nordisk's Ozempic. The Brazilian semaglutide market generates at least R$5bn ($960m) annually, and the drug's patent expired in March 2026. Rival EMS already secured approval for a competing product.

GLP-1 weight-loss drugs are reducing U.S. consumption of carbon-intensive foods like red meat and sugary drinks, leading to significant declines in food-system emissions. Clinical data shows users cut calorie intake by 21% and grocery spending by 5–6%, with Wall Street projecting billions in lost food sales by 2030. The shift aligns with federal dietary guidelines and could surpass climate policy in reducing emissions.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza). The study evaluated their effectiveness in a head-to-head analysis.

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza).

A new meta-study compared three GLP-1 medications: tirzepatide (Zepbound, Mounjaro), semaglutide (Wegovy, Ozempic), and liraglutide (Saxenda, Victoza) to determine their effectiveness.

GLP-1 weight-loss drugs may improve male fertility by enhancing testosterone levels and semen quality in obese men with low testosterone. A review of five trials found no suppression of male reproductive hormones and potential benefits for metabolic health, though more research is needed.

A new study suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may strengthen bones in Type 2 diabetes patients by 15%. This effect was described as an unexpected side benefit of the weight loss drugs.

A new study suggests that adults taking GLP-1 medications like Ozempic or Wegovy for weight loss are significantly reducing their physical activity, with decreases in daily steps and moderate-to-vigorous exercise. Researchers emphasize that exercise remains essential for preserving strength and long-term health when using these drugs, despite the observed decline in activity.

Medicare will cover weight loss drugs for adults 65 and older starting next month via a temporary government program. Novo Nordisk plans to seek Chinese regulatory approval for its Wegovy weight loss pill soon amid competition from generic drugmakers.

A study found that diabetes patients using semaglutide (Ozempic, Wegovy) had a 15% lower risk of fractures compared to others with type 2 diabetes. The analysis reviewed medical records and focused on adults with the condition.

Novo Nordisk CEO Mike Doustdar highlights the potential of the company's obesity drugs, such as Ozempic and Wegovy, to impact longevity and other healthcare areas beyond weight loss. The drugs' active ingredient, semaglutide, shows possible benefits for organ protection and slowing aging-related processes, even before significant weight loss. Investors are urging the company to diversify as competitors like Eli Lilly expand into broader markets.

A study of over 600,000 U.S. veterans found that GLP-1 drugs like semaglutide are associated with reduced risks of developing substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other drugs. These medications also correlate with fewer overdoses, hospitalizations, emergency visits, and drug-related deaths among individuals already struggling with addiction.

Telehealth companies offering GLP-1 weight loss medications face scrutiny after patients report severe adverse effects and dosage errors. Karleigh McClain was hospitalized following an overdose linked to a semaglutide prescription from a telehealth provider, highlighting concerns about medication safety and inadequate oversight in online healthcare services.

Weight-loss drugs like GLP-1s are easily accessible online, leading to concerns about overdoses and safety. The article specifically mentions semaglutide as an example of such drugs used for weight loss and obesity management.

A new study suggests GLP-1 weight-loss drugs like semaglutide and tirzepatide may significantly slow the progression of obesity-related cancers such as lung, breast, colorectal, and liver cancers. Conducted by Cleveland Clinic and to be presented at the 2026 ASCO Annual Meeting, the retrospective analysis found GLP-1 users had up to 50% lower risk of cancer advancing to stage 4 compared to patients taking DPP-4 inhibitors.

New NIH research reveals that semaglutide triggers varied responses in appetite-controlling brain cells, explaining why GLP-1 weight-loss drugs like Ozempic and Wegovy lose effectiveness over time. Scientists also identified a potential method to prolong the drugs' efficacy, helping patients overcome weight-loss plateaus.

A new analysis suggests Wegovy, a weight-loss drug, may carry a higher risk of a rare 'eye stroke' causing sudden vision loss compared to Ozempic. The study found the risk signal was nearly five times stronger for Wegovy despite both containing semaglutide.

The peptide market is experiencing rapid growth as GLP-1 weight-loss medications gain popularity, with largely unregulated peptides being sold through compounding pharmacies and unverified vendors. The FDA is evaluating whether to loosen regulations on several peptides, while compounding pharmacies have expanded to meet demand and offer dosing flexibility that commercial products cannot provide.

Semaglutide, also known as Ozempic and Wegovy, has been found to be highly effective in achieving significant weight loss in adults over 65, with participants losing an average of over 15% of their body weight and improving heart and metabolic health. This is a substantial improvement compared to placebo treatment. The study highlights the potential of semaglutide in helping older adults reach healthier weight levels.

The introduction of generic versions of Ozempic in Canada may lead to a decline in international revenue for Novo Nordisk's semaglutide. This marks a significant test case for the company. The generics will likely impact Novo Nordisk's revenue from Ozempic and Wegovy.

GLP-1 drugs like semaglutide and tirzepatide, popular for weight loss and diabetes management, offer cardiovascular and kidney benefits but require careful use. Dr. Meena T. Malhotra warns against common mistakes, emphasizing lifestyle changes, medical oversight, and avoiding online purchases without proper evaluation.

A new minimally invasive procedure called duodenal mucosal resurfacing may help prevent weight regain after discontinuing Ozempic or Wegovy. Clinical trials showed participants who underwent the treatment regained less weight compared to others, as the procedure renews the upper small intestine lining and potentially resets metabolism.

A study in Nature found genetic variations in the GLP1R and GIPR genes influence the effectiveness and side effects of GLP-1 receptor agonists like semaglutide and tirzepatide. Patients with specific gene variants experienced modest weight loss boosts and increased nausea risks, highlighting potential for personalized treatment approaches.

A study analyzing Reddit posts from 67,000 users revealed previously undocumented side effects of GLP-1 medications like semaglutide and tirzepatide, including menstrual irregularities, psychiatric symptoms, and fatigue. Researchers from the University of Pennsylvania highlight discrepancies between clinical trial data and real-world user experiences.